REPATH LAUNCH
15 September 2026
Global
Genspect formally launches REPATH — its Re-psychopathologisation Campaign — on 15 September 2026, with hosts Stella O'Malley and Mia Hughes setting out the case for replacing automatic affirmation with thorough psychiatric assessment and differential diagnosis. The campaign's core demand mirrors the central recommendation of the Cass Review: that gender dysphoria in young people should receive the same rigorous clinical evaluation as any other complex mental health presentation, not an administrative pathway insulated from standard diagnostic scrutiny.
On 15 September 2026, Genspect formally launches REPATH — its Re-psychopathologisation Campaign — and hosts Stella O'Malley and Mia Hughes use the occasion to explain, in detail, what the campaign is actually arguing for. The name is deliberately chosen and deliberately clinical. To re-psychopathologise is not to stigmatise gender non-conformity, nor to pathologise those who identify as transgender. It is to insist that the distress accompanying such identification warrants the same rigorous psychiatric evaluation as any other complex mental health presentation, and that a diagnostic framework — rather than an ideological one — should govern clinical response. The distinction matters because the past decade saw affirmation become the default in many clinical settings, including in the United Kingdom. Disclosure of a transgender identity was increasingly treated as self-evidencing — a statement that settled rather than opened clinical inquiry. The Cass Review, published in April 2024 after the most comprehensive examination of gender medicine in NHS history, found this approach to be clinically unsound. Dr Hilary Cass concluded that young people deserved the same careful, exploratory assessment applied to any other presentation of adolescent distress, and that the absence of that assessment had left patients without adequate support and parents without adequate information. REPATH frames its campaign as the international counterpart to what the Cass Review recommended domestically. The argument is that automatic affirmation did not arise in the United Kingdom alone: it spread across healthcare systems, legal frameworks, school policies and professional bodies with similar speed and with similarly inadequate evidence behind it. Restoring a psychiatric understanding means restoring the conditions under which thorough differential diagnosis can take place — asking what else might explain a young person's distress before any clinical pathway is decided. O'Malley and Hughes are well positioned to present this argument. O'Malley, a psychotherapist with clinical experience working with gender-questioning clients, has long made the case that many young people arriving at gender services carry co-occurring conditions — anxiety, depression, autism, trauma — that went underexplored under affirmation-led protocols. Hughes, a researcher whose work has focused on scrutinising the international evidence base for gender medicine, approaches the same problem from a systematic analytical perspective. Between them they represent the two disciplines — clinical practice and research — that REPATH is seeking to re-centre. For those following UK policy developments, the campaign's launch arrives at a meaningful moment. NHS England has already moved, in the wake of the Cass Review, to restructure paediatric gender services around multidisciplinary assessment teams and to suspend new prescriptions of puberty blockers outside research protocols. The practical question now is whether a parallel shift in clinical culture — one that restores the primacy of differential diagnosis and psychological care — can be embedded durably across training programmes, commissioning decisions and professional guidance. REPATH represents an organised international effort to make that case and to hold institutions accountable for the gap between stated commitment and clinical practice.
